Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of ampreloxetine (TD-9855) in symptomatic neurogenic orthostatic hypotension due to primary autonomic failure
2019-002425-30Phase 3Unknown
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ampreloxetine in Neurogenic Orthostatic Hypotension (nOH), sponsored by Theravance Biopharma, Inc. Primary endpoint: Primary safety and tolerability endpoints. Status: unknown.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on 2019-002425-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002425-30.